{"type":"trials","record":{"id":8,"source_id":"clinicaltrials-gov","external_id":"NCT05706389","title":"Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?","brief_summary":"Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Contrary to popular opinion that aging is irreversible, advances in geroscience research have demonstrated that aging is modifiable and inhibiting or activating specific molecular pathways can improve healthspan and extend lifespan in model organisms. Advocates of geroscience take the view that age-related chronic diseases are best treated by slowing the aging process, rather than using the prevailing disease-centric approach of addressing each disease alone. Thus, the concept is that biological aging, rather than chronological aging, is amenable to intervention. In this regard, geroscientists are at the forefront of longevity medicine in rigorously testing novel supplements, drugs and other prophylactics that can enhance healthspan. Some of these interventions involve repurposing existing drugs such as rapamycin, a well-known immunosuppressant, at different dosing regimens to specifically target biological hallmarks of aging. This study will investigate the effects of alpha-ketoglutarate (AKG), an endogenous metabolite, on biomarkers of aging in middle-aged residents of Singapore.","overall_status":"Active Not Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"National University of Singapore","enrollment":120,"countries":["Singapore"],"start_date":"2023-02-24","completion_date":"2027-01-15","last_update_date":"2026-05-26","source_url":"https://clinicaltrials.gov/study/NCT05706389","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:44:58.543517+00:00","last_seen_at":"2026-09-25T06:15:13.984+00:00","metadata":{"sex":"ALL","acronym":"ABLE","age_range":"40 Years to 60 Years","comparator":"Placebo","organization":"National University of Singapore","interventions":["Ca-AKG"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in blood DNA methylation status, years — from baseline to end of intervention (6 months)","Complete blood count — from baseline to end of intervention (6 months)","Carotid-femoral Pulse Wave Velocity change — from baseline to end of intervention (6 months)","Central Blood pressure change — from baseline to end of intervention (6 months)","Body Mass Index (BMI) change — from baseline to end of intervention (6 months)","Brachial Blood pressure change — from baseline to end of intervention (6 months)","Waist/hip ratio change — from baseline to end of intervention (6 months)","Bone Mineral Density, g/cm2 change — from baseline to end of intervention (6 months)","Fat-free mass, change (kg) — from baseline to end of intervention (6 months)","Fat mass, change (kg) — from baseline to end of intervention (6 months)","Handgrip strength change (kg) — from baseline to end of intervention (6 months)","8-RM leg extension change (kg) — from baseline to end of intervention (6 months)","Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption (V̇O2), L/min — from baseline to end of in…","Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption per kg body weight (V̇O2/kg), L/min/kg — f…","Cardiopulmonary exercise test (CPET): change in lactate — from baseline to end of intervention (6 months)","Cardiopulmonary exercise test (CPET): change in heart rate — from baseline to end of intervention (6 months)","Cardiopulmonary exercise test (CPET): aerobic and anaerobic threshold change — from baseline to end of intervention (6…","Cardiopulmonary exercise test (CPET): excess post-exercise oxygen consumption change — from baseline to end of interven…","Change in Skin autofluorescence, au — from baseline to end of intervention (6 months)","Change in Quality-of-Life questionnaires (SF-36 questionnaires) — from baseline to end of intervention (6 months)"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE","source_has_results":false},"controlled_terms":["Aging","Ca-AKG"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: alpha-ketoglutarate.","quality_checked_at":"2026-09-25T06:15:15.562724+00:00","duplicate_cluster_key":"id:nct05706389","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-02-24 to 2027-01-15","comparator":"Placebo","confidence":"structured-source","population":"ALL · 40 Years to 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:13.993Z","intervention":["Ca-AKG"],"participants":120,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in blood DNA methylation status, years — from baseline to end of intervention (6 months)","Complete blood count — from baseline to end of intervention (6 months)","Carotid-femoral Pulse Wave Velocity change — from baseline to end of intervention (6 months)","Central Blood pressure change — from baseline to end of intervention (6 months)","Body Mass Index (BMI) change — from baseline to end of intervention (6 months)","Brachial Blood pressure change — from baseline to end of intervention (6 months)","Waist/hip ratio change — from baseline to end of intervention (6 months)","Bone Mineral Density, g/cm2 change — from baseline to end of intervention (6 months)","Fat-free mass, change (kg) — from baseline to end of intervention (6 months)","Fat mass, change (kg) — from baseline to end of intervention (6 months)","Handgrip strength change (kg) — from baseline to end of intervention (6 months)","8-RM leg extension change (kg) — from baseline to end of intervention (6 months)","Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption (V̇O2), L/min — from baseline to end of in…","Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption per kg body weight (V̇O2/kg), L/min/kg — f…","Cardiopulmonary exercise test (CPET): change in lactate — from baseline to end of intervention (6 months)","Cardiopulmonary exercise test (CPET): change in heart rate — from baseline to end of intervention (6 months)","Cardiopulmonary exercise test (CPET): aerobic and anaerobic threshold change — from baseline to end of intervention (6…","Cardiopulmonary exercise test (CPET): excess post-exercise oxygen consumption change — from baseline to end of interven…","Change in Skin autofluorescence, au — from baseline to end of intervention (6 months)","Change in Quality-of-Life questionnaires (SF-36 questionnaires) — from baseline to end of intervention (6 months)"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"alpha-ketoglutarate","is_published":true,"match_reasons":["Title contains controlled term: alpha-ketoglutarate.","Abstract contains controlled term: alpha-ketoglutarate, akg.","Source terminology contains: akg.","Title supplies longevity context: biological age.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Alpha-ketoglutarate","slug":"alpha-ketoglutarate"}},{"topic_slug":"biological-age-biomarkers","is_published":true,"match_reasons":["Title contains controlled term: biological age.","Title supplies longevity context: biological age.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Biological age biomarkers","slug":"biological-age-biomarkers"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/8","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}